Cargando…
PCSK9 inhibition potentiates cancer immune checkpoint therapy
Despite its great success, cancer immune therapy is still of limited efficacy in the majority of cancer patients(1,2). Many efforts are underway to identify novel approaches to enhance immune checkpoint therapy(3–5). Here we show that inhibition of PCSK9, a key protein in regulating cholesterol meta...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770056/ https://www.ncbi.nlm.nih.gov/pubmed/33177715 http://dx.doi.org/10.1038/s41586-020-2911-7 |